Press coverage about Cytosorbents (NASDAQ:CTSO) has trended positive this week, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cytosorbents earned a media sentiment score of 0.31 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 44.1222106124582 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

A number of equities research analysts have recently issued reports on the company. Maxim Group set a $12.00 price objective on Cytosorbents and gave the stock a “buy” rating in a research note on Monday, January 8th. ValuEngine cut Cytosorbents from a “hold” rating to a “sell” rating in a research note on Friday, December 15th. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of Cytosorbents in a research note on Tuesday, September 26th. Finally, B. Riley reiterated a “buy” rating and set a $11.25 price objective on shares of Cytosorbents in a research note on Friday, November 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $10.60.

Cytosorbents (CTSO) traded down $0.03 during mid-day trading on Thursday, hitting $7.38. The company had a trading volume of 87,174 shares, compared to its average volume of 165,945. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.36 and a quick ratio of 3.17. The firm has a market cap of $211.60, a price-to-earnings ratio of -19.41 and a beta of -0.54. Cytosorbents has a 1-year low of $3.30 and a 1-year high of $7.90.

Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Thursday, November 9th. The medical research company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). Cytosorbents had a negative return on equity of 233.72% and a negative net margin of 67.83%. research analysts predict that Cytosorbents will post -0.26 EPS for the current fiscal year.

In related news, CFO Kathleen P. Bloch sold 32,400 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $7.30, for a total transaction of $236,520.00. Following the transaction, the chief financial officer now directly owns 248,638 shares of the company’s stock, valued at approximately $1,815,057.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kathleen P. Bloch sold 12,400 shares of the business’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $7.75, for a total value of $96,100.00. Following the transaction, the chief financial officer now directly owns 241,038 shares in the company, valued at $1,868,044.50. The disclosure for this sale can be found here. Insiders have sold a total of 48,800 shares of company stock worth $360,620 over the last three months. 5.60% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: “Positive Press Coverage Somewhat Unlikely to Affect Cytosorbents (CTSO) Stock Price” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2018/01/18/positive-press-coverage-somewhat-unlikely-to-affect-cytosorbents-ctso-stock-price.html.

Cytosorbents Company Profile

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Insider Buying and Selling by Quarter for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.